LAX.SH
VENUS REMEDIES LIMITED·PHARMACEUTICALS 66.37·Pharmaceuticals & Biotechnology Companies
Price
1,441.5
-4.78%52W Range
Market Cap
₹1,926.85 Cr
Traded: ₹10.84 Cr (0.56%) 0.0x
Free Float: ₹959.57 Cr (1.13% of FF traded)
Volume · 60D trend
74.32 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +7.0% | +7.0% | +12.0% | -- | +20.0% | Accelerating |
| Profit | +51.0% | +22.0% | +57.0% | -- | +174.0% | Accelerating |
| Return | +33.0% | +30.0% | +83.0% | +203.0% | -- | Accelerating |
| ROE | +5.0% | +10.0% | +11.0% | -- | -- | Accelerating |
Quarterly Results
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 179 | 259 | 180 | 193 | 137 | 195 | 177 | 170 | 109 | 195 | 143 | 168 | 95 | 156 | 117 |
| Expenses | 145 | 196 | 143 | 162 | 122 | 166 | 158 | 163 | 97 | 176 | 131 | 150 | 85 | 131 | 109 |
| Operating Profit | 34 | 63 | 38 | 31 | 15 | 29 | 18 | 8 | 11 | 19 | 12 | 18 | 10 | 25 | 8 |
| Other Income | 3 | 5 | 3 | 2 | 3 | 7 | 12 | 8 | 2 | 4 | 2 | 3 | 2 | 3 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 6 | 6 | 6 | 7 | 6 | 8 | 8 | 7 |
| Profit Before Tax | 30 | 62 | 33 | 26 | 13 | 31 | 25 | 9 | 7 | 17 | 8 | 14 | 5 | 20 | 5 |
| Tax % | 24.0% | 23.0% | 24.0% | 24.0% | 24.0% | 32.0% | 21.0% | 61.0% | 82.0% | 40.0% | 12.0% | 31.0% | 77.0% | 44.0% | 28.0% |
| Net Profit | 23 | 48 | 26 | 20 | 10 | 21 | 20 | 4 | 1 | 11 | 7 | 10 | 1 | 11 | 3 |
| Exceptional Items | -- | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 17.2 | 35.5 | 19.1 | 15.1 | 7.2 | 15.7 | 14.7 | 2.6 | 0.9 | 7.9 | 5.1 | 7.4 | 0.9 | 8.3 | 2.5 |
| Sales Growth (YoY) | -- | 33.0% | 2.1% | 13.3% | 26.3% | -0.1% | 23.1% | 1.4% | 14.2% | 25.4% | 22.7% | 19.9% | -33.5% | 9.3% | -- |
| Sales Growth (QoQ) | -- | 43.9% | -6.7% | 40.9% | -29.7% | 10.2% | 4.1% | 56.0% | -44.1% | 36.4% | -14.9% | 76.8% | -39.1% | 33.3% | -- |
| OP Growth (YoY) | 126.7% | 117.2% | 111.1% | 287.5% | 36.4% | 52.6% | 50.0% | -55.6% | 10.0% | -24.0% | 50.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | -46.0% | 65.8% | 22.6% | 106.7% | -48.3% | 61.1% | 125.0% | -27.3% | -42.1% | 58.3% | -33.3% | 80.0% | -60.0% | 212.5% | -- |
| Profit Growth (YoY) | -- | 126.0% | 103.0% | 474.0% | 687.0% | 100.0% | 84.0% | -65.0% | 3.0% | -5.0% | 108.0% | 86.0% | -83.0% | 4709.0% | -42.0% |
| EPS Growth (YoY) | -- | 126.2% | 30.6% | 472.6% | 689.0% | 99.9% | 186.3% | -64.7% | 3.4% | -5.0% | 108.1% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 85.7% | 27.1% | 109.8% | -54.3% | 7.2% | 457.4% | 189.0% | -88.4% | 53.5% | -31.2% | 745.5% | -89.4% | 236.2% | -- |
| OP Margin | -- | 24.3% | 21.1% | 16.1% | 10.9% | 14.9% | 10.2% | 4.7% | 10.1% | 9.7% | 8.4% | 10.7% | 10.5% | 16.0% | 6.8% |
| Net Margin | -- | 18.5% | 14.4% | 10.4% | 7.3% | 10.8% | 11.3% | 2.4% | 0.9% | 5.6% | 4.9% | 6.0% | 1.1% | 7.0% | 2.6% |
| Material Cost % | -- | 46.1% | 47.9% | 55.7% | 54.0% | 52.9% | 62.4% | 63.3% | 53.1% | 61.5% | 62.2% | 58.1% | 50.4% | 55.9% | 60.2% |
| Employee Cost % | -- | 9.5% | 11.6% | 11.9% | 14.8% | 10.8% | 11.1% | 12.7% | 16.8% | 10.1% | 12.1% | 11.0% | 16.8% | 9.3% | 13.1% |
| P/S | 2.38 | 2.94 | 2.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 16.58 | 22.02 | 20.34 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.91 | 3.81 | 2.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50As per the file enclosed.
As per the pdf enclosed.
Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve As per the pdf enclosed.
Compliance under Reg 74(5) of SEBI (DP) regulations.
As per file enclosed.
Newspaper publication of shareholder notice on Transfer of physical shares.
Newspaper publication for shareholders awareness on transfer of physical shares.
As per the pdf enclosed.
As per file enclosed.
As per the file enclosed.
As per enclosed file.
As per file enclosed.
As per the file enclosed.
Newspaper publication of 37th AGM Notice.
As per the pdf enclosed.
Annual report for FY 2025-26.
Annual report for the FY 2025-26.
As per the pdf enclosed.
As per the pdf enclosed.
As per pdf enclosed.
As per pdf enclosed.
As per the file enclosed.
Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/07/2026 ,inter alia, to consider and approve This is to inform you that the ....
As per the pdf enclosed.
Copy of newspaper publication for AGM prior Notice.
Closure of Trading window
As per file enclosed.
As per enclosed file.
AS per file enclosed.
As the file enclosed.
As per file enclosed
Appointments & reappointments of directors.
As per the file enclosed
As per the pdf enclosed
Social media Post on KYC updation.
Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve Board meeting scheduled for ....
Board meeting is scheduled for 26th May 2026.
Annual Secretarial Compliance report for the Year ended on 31st March as per Reg 24(A) of SEBI LODR.
Newspaper publication of Notice to shareholders about transfer of physical shares as per SEBI circular.
Disclosure of social media post on details about Transfer of physical shares.
Compliance certificate under Reg 74(5) of SEBI DP regulations for the quarter ended on 31st March 2026.
Social Media post informing shareholder about limited period window for physical transfer of shares.
Disclosure under reg 31(4) of SEBI SAST regulations 2011.
Closure of trading window
Social media Post pertaining to Transfer of physical shares.
Disclosure.
Copy of newspaper publication of UFR as on 31st December 2025.
Unaudited Standalone and Consolidated Financial Results as on 31st December 2025
Outcome of Board meeting dated 29th January 2026
Venus Remedies awarded with Rs.11,77,50,000 incentive under PLI scheme.
Annual Reports
14Held by ETFs
1 ETFs hold VENUSREM · sorted by weight